Objective
To identify the receptors in brain which are targets for the antipsychotic effect of neuroleptic drugs. This information will be a cornerstone in future industrial antipsychotic drug development.
To develop principles for more effective, safe and tolerable clinical antipsychotic drug treatment of the more than l million currently treated patients in Europe.
More than l million patients within the EU suffer from schizophrenia and are on long-term treatment with antipsychotic drugs. The direct health care costs for schizophrenia are higher than 10 billion ECU's per year. Insufficient treatment response and intolerable side effects lead to relapse in psychosis and a chronic course. The industrial development of more effective drugs is hampered by the high costs. At least 150 million ECU's are required to develop a new antipsychotic. To improve clinical treatment and to speed up drug development it is of central importance to identify the targets for antipsychotic drug effects in the human brain. Research now benefits from the development of new imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). The sensitivity of these techniques is unsurpassed for direct studies on drug binding in the living human brain. High binding to receptors for the neurotransmitter dopamine has been demonstrated by PET in large brain nuclei which are related to motor side effects. We have now developed the first method in the world that allows quantitative examination of dopamine receptor binding in the small limbic and cortical brain regions which are assumed to be "sites" for the antipsychotic effect. To obtain the required number of patients three PET-centres will use the same strategy to examine patients treated with antipsychotic drugs. Relationships will be examined among dose, drug concentration in plasma and degree of drug binding in brain. Principles will thereby be identified for optimal clinical treatment of schizophrenia. Biochemical targets for antipsychotic drug effects will be identified in distinct regions of the human brain . The new data can be used in industrial programs to tailor more selective, efficacious and tolerable drugs for the treatment of schizophrenia SPECT is a widespread technique with potential for routine clinical optimisation of treatment. To validate the SPECT-methodology a direct clinical comparison will be made between PET and SPECT.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences clinical medicine psychiatry schizophrenia
- natural sciences physical sciences theoretical physics particle physics photons
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
171 76 STOCKHOLM
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.